Fripnit Plus 300 mg, 300 mg Tablet

Fripnit Plus 300 mg, 300 mg Tablet

S4
PDF Leaflet Revision Date: 02 May 2023


Clinical Summary

Quick overview from the medicine insert

Indication

Prevention of active tuberculosis in high-risk patients with latent tuberculosis infection.

Dosage (summary)

Once-weekly for 12 weeks; adults: rifapentine max 900 mg, isoniazid max 900 mg.

Special Populations

  • Elderly
  • Hepatic impairment
  • Renal impairment

Pregnancy & Breastfeeding

Not recommended during pregnancy; safety in lactation not established.

Key Drug Interactions

  • Antiretroviral medicines
  • Hormonal contraceptives
  • Antacids

Contraindications

  • Hypersensitivity
  • Severe renal failure
  • Acute liver disease
  • Alcoholism

Common side effects

  • Hypersensitivity
  • Nausea
  • Hepatitis
  • Headache

Counselling Points

  • Take with food
  • Avoid tyramine-rich foods
  • Report signs of hypersensitivity

Serious warnings

  • Hepatotoxicity
  • Severe skin reactions
  • Monitor liver function
Important Disclaimer

The Fripnit Plus 300 mg, 300 mg Tablet professional information leaflet below is the property of Pharma Dynamics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

Healthcare Professionals Only

This content is for registered healthcare professionals

Sign in or create a free account to read the full package insert.

Free for HPCSA-registered professionals. Powered by Medinsert.

Successfully Stashed! 💊

This package insert has been safely stored in your digital medical cabinet. No prescription needed to view it later!

View My Favourites